PLATELETS COMPRISING EXOGENOUS POLYPEPTIDES AND USES THEREOF
Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.
1 . A platelet comprising an exogenous polypeptide.
2 . The platelet of claim 1 , which was produced by a process comprising introducing into the platelet an exogenous nucleic acid encoding the exogenous polypeptide.
3 . The platelet of claim 1 , which was produced by a process comprising introducing into a nucleated platelet precursor cell an exogenous nucleic acid encoding the exogenous polypeptide.
4 . The platelet of claim 1 , wherein the nucleated platelet precursor cell is a megakaryocyte, a hematopoietic stem cell, an induced pluripotent stem cell, or an embryonic stem cell.
5 . The platelet of claim 1 , which was produced by introducing the exogenous polypeptide into the platelet by subjecting the platelet to a controlled cell injury.
6 . The platelet of claim 5 , wherein the controlled cell injury caused a perturbation in the cell membrane of the platelet.
7 . The platelet of claim 5 , wherein the controlled cell injury comprises cell deformation, electroporation, sonoporation, liposomal transfection, or salt-based transfection.
8 . The platelet of claim 5 , wherein the controlled cell injury comprises cell deformation.
9 . The platelet of claim 5 , wherein the controlled cell injury comprises cell squeezing.
10 . The platelet of claim 2 , which was produced by introducing the exogenous nucleic acid into the platelet by subjecting the platelet to a controlled cell injury.
11 . The platelet of claim 10 , wherein the controlled cell injury caused a perturbation in the cell membrane of the platelet.
12 . The platelet of claim 10 , wherein the controlled cell injury comprises cell deformation, electroporation, sonoporation, liposomal transfection, or salt-based transfection.
13 . The platelet of claim 10 , wherein the controlled cell injury comprises cell deformation.
14 . The platelet of claim 10 , wherein the controlled cell injury comprises cell squeezing.
15 . The platelet of claim 3 , which was produced by introducing the exogenous nucleic acid into the nucleated platelet precursor cell by subjecting the platelet to a controlled cell injury.
16 . The platelet of claim 15 , wherein the controlled cell injury caused a perturbation in the cell membrane of the nucleated platelet precursor cell.
17 . The platelet of claim 15 , wherein the controlled cell injury comprises cell deformation, electroporation, sonoporation, liposomal transfection, or salt-based transfection.
18 . The platelet of claim 3 , which was produced by introducing the exogenous nucleic acid into the nucleated platelet precursor cell using viral transduction.
19 . The platelet of claim 15 , wherein the controlled cell injury comprises cell squeezing.
20 . The platelet of claim 3 , wherein the exogenous nucleic acid comprises DNA.
21 . The platelet of claim 3 , wherein the exogenous nucleic acid comprises RNA.
22 . The platelet of claim 1 , wherein the exogenous polypeptide comprises an enzyme, a cytokine, an antibody, a hormone, a receptor, or a functional fragment thereof.
23 . The platelet of claim 1 , wherein the exogenous polypeptide is intracellular.
24 . The platelet of claim 1 , wherein the exogenous polypeptide is at the surface of the platelet.
25 . The platelet of claim 1 , wherein the exogenous polypeptide comprises a transmembrane domain.
26 . The platelet of claim 1 , which comprises at least 1,000 copies of the exogenous polypeptide.
27 . The platelet of claim 1 , which is a human cell.
28 . A pharmaceutical composition comprising the platelet of claim 1 and a pharmaceutically acceptable carrier.
29 . A method of producing the platelet of claim 1 , comprising:
introducing into a nucleated platelet precursor cell an exogenous nucleic acid encoding the exogenous polypeptide; and
culturing the nucleated platelet precursor cell to produce the platelet.
30 . A method of producing the platelet of claim 1 , comprising introducing into a platelet an RNA molecule encoding the exogenous polypeptide.
31 . A method of producing the platelet of claim 1 , comprising introducing the exogenous polypeptide into a platelet by subjecting the platelet to a controlled cell injury.
32 . The method of claim 31 , wherein the controlled cell injury caused a perturbation in the cell membrane of the platelet.
33 . The method of claim 31 , wherein the controlled cell injury comprises cell deformation, electroporation, sonoporation, liposomal transfection, or salt-based transfection.
34 . The method of claim 31 , wherein the controlled cell injury comprises cell deformation.
35 . The method of claim 31 , wherein the controlled cell injury comprises cell squeezing.
36 . A method of treating a disease in a subject in need thereof, the method comprising administering to the subject the platelet of claim 1 .
37 . The method of claim 36 , wherein the disease comprises a metabolic disease, a cancer, a clotting disease, or an anti-clotting disease.